Fig. 4From: Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 dataThe predicted probabilities of experiencing a DLT and corresponding 95 % prediction intervals for the conservative prior skeleton approach in the CRM method prior to the inclusion of any dose-toxicity dataBack to article page